Novartis Investigative Site

Bath BS2 8BJ

0 studies enrolling now · 10 studies all time

What they study most

Ankylosing Spondylitis, Cardiovascular Disease, Chronic Obstructive Pulmonary Disease (COPD), Heart Failure With Reduced Ejection Fraction, Hormone Receptor Positive Breast Cancer, Leukaemia, Lymphocytic, Chronic, Muscle Wasting (Atrophy) After Hip Fracture Surgery, Non-radiographic Spondyloarthritis, Psoriatic Arthritis, Systemic Juvenile Idiopathic Arthritis, Type 2 Diabetes Mellitus

Studies at this site

• Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar) — Completed
• Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer — Completed
• Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis — Completed
• Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery — Completed
• Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis — Completed
• Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia — Stopped early
• An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever. — Completed
• Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients — Completed
• Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases) — Stopped early
• A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) — Completed